Jul. 14 at 11:06 AM
$RGNX Fine, I will give you a thought or 2. Below is a chart of potential drugs in pipeline for approval. Shares doubled when Hunters Syndrome decision was reversed and good odds of approval...and that is the smallest market. If even 2 of 4 drugs get approved, and odds are well above 80%, then you will be a happy camper.
Program Next Regulatory Event FDA Approval Odds EMA Approval Odds Peak Worldwide Sales
RGX-202 Duchenne BLA expected Q3 2026 75% 70%
$1.5–3.0B
NAVSUNLI (RGX-121) Hunter syndrome BLA resubmission 80% 75%
$300–700M
ABBV-RGX-314 Wet AMD Following successful Phase 3 65% 60%
$3–6B
ABBV-RGX-314 Diabetic Retinopathy Following Phase IIb/III 45% 40%
$1–3B
